Accessibility Menu
Curanex Pharmaceuticals logo

Curanex Pharmaceuticals(NASDAQ) CURX

Current Price$0.21
Market Cap$5.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)-95%
5 YearN/A
1 YearN/A
1 Month-27%
Curanex Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.202026-07-22
Curanex Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.62%USD 0.222026-07-15
1 month-26.8%USD 0.282026-06-22
3 month-54.14%USD 0.442026-04-23
Year to date-38.54%USD 0.332025-12-31
Since inception-94.97%USD 4.022025-08-26

Curanex Pharmaceuticals Financials at a Glance

Market Cap

$5.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$7.24M

EPS (TTM)

-$0.26

P/E Ratio

-0.79

Dividend

$0.00

Beta (Volatility)

1.35 (Average)

Price

$0.21

Volume

500

Open

$0.21

Previous Close

$0.21

Daily Range

$0.21 - $0.21

52-Week Range

$0.20 - $9.18

Estimated Earnings Date

Mar 30, 2026

CURX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Curanex Pharmaceuticals

Curanex develops plant-based drugs for people with inflammatory diseases. Its main product aims to help those with conditions like ulcerative colitis. The company focuses on early-stage research, not yet selling any products.

What’s Cooking in the Lab?

  • Phyto-N (Lead Candidate): A plant extract in preclinical testing for inflammatory diseases; 0% of revenue (no sales).
  • Ulcerative Colitis Program: Targets chronic colon inflammation; main focus for future clinical trials.
  • Atopic Dermatitis Program: Aims to address skin inflammation; still in early research.
  • COVID-19, Diabetes, NAFLD, Gout: Exploring use of Phyto-N for these conditions; all in preclinical stage.
  • Discontinued Acne Program: Stopped after early studies showed limited potential; no patent pursued.

Growth Spurts and Science Sprints

  • Completed IPO in August 2025, raising $15 million in gross proceeds.
  • Acquired preclinical data and patents from Duraviva Pharma in 2024.
  • Launched pilot-scale manufacturing of Phyto-N in February 2026.
  • Established a scientific advisory board in March 2026 to guide development.

Why Curanex Is a Bit Different

Curanex focuses on botanical drugs, which are plant-based mixtures, not single chemicals. Its main drug candidate is based on a plant used in Chinese medicine for decades. The company invests in research partnerships and aims to identify which patients may benefit most from its drugs.

Five Things You Need to Know

  • No revenue in 2025 or 2024; company is pre-commercial.
  • Operating loss was $4.24 million in 2025, up 1,061% from 2024.
  • Research and development expenses were $2.99 million in 2025, up from $74,676 in 2024.
  • Cash and equivalents were $5.0 million at December 31, 2025.

Bottom Line

Curanex is an early-stage biotech focused on plant-based drugs for inflammation. The company is investing heavily in research but has not yet reached the market.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Jun Liu

Website

www.curanexpharma.com

Headquarters

Jericho, NY 11753, US

CURX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-85.41%

Return on Capital

-36.65%

Return on Assets

-86.05%

Earnings Yield

-1.27%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

28.36M

Volume

500

Avg. Volume

88.99K

Financials (TTM)

Gross Profit

-$35.04K

Operating Income

-$7.28M

EBITDA

-$2.95M

Operating Cash Flow

-$11.29M

Capital Expenditure

$0.00

Free Cash Flow

-$11.29M

Cash & ST Invst.

$4.02M

Total Debt

$311.00K

Curanex Pharmaceuticals Performance Analysis

Curanex Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Curanex Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Curanex Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-12-31USD -0.00N/A
20242024-12-31USD -0.011757.1%
20252025-12-31USD -0.151046.9%
Curanex Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3056.0%
Q32025-09-30-1718.2%
Q42025-12-31-200.0%
Q12026-03-318.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$35.04K

N/A

Gross Margin

0.00%

N/A

Market Cap

$5.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$955.90K

N/A

Employees

6

N/A

Net Income

-$3.15M

-2189.7%

EBITDA

-$3.15M

-2489.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$4.02M

+1920.0%

Total Debt

$311.00K

+6.8%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$203.91K

-10.8%

Short Term Debt

$107.09K

+71.0%

Return on Assets

-86.05%

N/A

Return on Invested Capital

-87.96%

N/A

Free Cash Flow

-$954.56K

-536.6%

Operating Cash Flow

-$954.56K

-536.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PULMPulmatrix, Inc.
$1.69-0.59%
BCTXBriaCell Therapeutics Corp.
$3.60-4.00%
CUPRCuprina Holdings (Cayman) Limited Class A Ordinary Shares
$3.30-13.84%
CRISCuris, Inc.
$4.94+4.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$23.04+0.04%
ONDSOndas
$8.00+0.04%
SMCISuper Micro Computer
$30.56+0.20%
AALAmerican Airlines Group
$14.79-0.03%

Questions About CURX

What is the current price of Curanex Pharmaceuticals?

Curanex Pharmaceuticals is trading at $0.21 per share.

What is the 52-week range for Curanex Pharmaceuticals?

Over the past 52 weeks, Curanex Pharmaceuticals has traded between $0.20 and $9.18.

How much debt does Curanex Pharmaceuticals have?

As of the most recent reporting period, Curanex Pharmaceuticals reported total debt of $311.00K.

How much cash does Curanex Pharmaceuticals have on hand?

Curanex Pharmaceuticals reported $4.02M in cash and cash equivalents in its most recent financial results.

What is Curanex Pharmaceuticals’s dividend yield?

Curanex Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services